Valion Bio VBIO Estimates

NASDAQ VBIO
$2.20 -0.20 (-8.33%)
At close: Sep 10, 2026 · 4:00 PM EDT
Analyst Estimates

Valion Bio, Inc. Revenue Estimates

Periods 16
Next Period Q4 24
Consensus 1.37 M

Analysts expect Valion Bio, Inc. to report revenue of 1.37 M for Q4 24, against a range of 1.32 M to 1.42 M. The most recent reported quarter, Q3 24, came in at 126,000.00, a 90.3% miss against the 1.30 M consensus.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Reported (Actual) 376,000.00161,000.00282,000.00356,000.00334,000.00140,000.00126,000.00--------
High Estimate 558,208.33614,566.08775,914.401.36 M1.08 M1.25 M1.37 M1.42 M1.93 M601,607.07506,539.845.35 M3.28 M854,398.22543,490.61
Low Estimate 460,196.07575,321.22697,716.201.17 M972,238.161.09 M1.23 M1.32 M1.70 M548,490.95437,338.464.85 M2.77 M784,016.82469,366.67
Consensus Estimate 509,202.20594,943.65736,815.301.27 M1.03 M1.17 M1.30 M1.37 M1.82 M575,049.01471,939.155.10 M3.03 M819,207.52506,428.64
Analyst Estimates

Valion Bio, Inc. Earnings Per Share (EPS) Estimates

Periods 12
Next Period Q4 24
Consensus -2,268.54

Analysts expect Valion Bio, Inc. to report earnings per share of -2,268.54 for Q4 24, against a range of -2,376.15 to -2,160.93. The most recent reported quarter, Q3 24, came in at -97.75, a 96.0% beat against the -2,431.34 consensus.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25
Reported (Actual) -4,670.00-2,980.00-629.003,860.00-429.25-136.00-97.75-----
High Estimate -4,132.54-3,391.52-3,007.35-2,683.13-2,641.68-2,607.18-2,330.96-2,160.93-269.441,929.071,556.47-3,460.32
Low Estimate -4,841.84-3,626.48-3,311.15-3,125.33-3,044.78-2,841.50-2,531.72-2,376.15-309.281,729.071,379.89-3,695.28
Consensus Estimate -4,487.19-3,509.00-3,159.25-2,904.23-2,843.23-2,724.34-2,431.34-2,268.54-289.361,829.071,468.18-3,577.80